AFT Pharmaceuticals Limited (AFP) Q4 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you for standing by and welcome to the AFT Pharmaceuticals 2023 Full Year Results Analyst Briefing. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, press the star one again. For operator assistance throughout the call, please press star zero. And finally, I would like to advise all participants that this call is being recorded. Your speakers today are Dr. Hartley Atkinson, CEO, and Malcolm Tovey, CFO. I'd now like to welcome Dr. Hartley Atkinson, CEO, to begin the conference. Dr. Hartley, over to you. Good. Thank you very much. Thank you, everyone, for joining the call today. So, look, what I'd like to do is just to flick through the presentation. I'll do some of it, and Malcolm will do other parts, the financial parts, and then, as you said, questions. So, obviously, there's page number one, which refers to this full financial year. Then page number two is the standard disclaimer, so if you can please read that in your own time. Page number three, basically what we're saying is we're pleased to be declaring our maiden dividend and we're pleased to also have yet another year of record revenue. In fact, if you look at the graph on the bottom, you can see that over the last 10 years, we've almost, not quite, but almost quadrupled revenue, which we're really pleased with just getting that ongoing growth. And if anything, we're pleased to see it starting to almost slightly hockey stick as well, which is what we've been working hard to achieve. So the overall operating revenue grew 20% to $157 million, with...